• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 肺部和嗅觉功能障碍:趋化因子 CXCL10 是否为共同决定因素?

COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?

机构信息

Hospital Nacional de Parapléjicos, FENNSI Group, SESCAM, Toledo, Spain.

Instituto Cajal-CSIC, Spanish Research Council/Consejo Superior de Investigaciones Científicas-CSIC, Madrid, Spain.

出版信息

Neuroscientist. 2021 Jun;27(3):214-221. doi: 10.1177/1073858420939033. Epub 2020 Jul 13.

DOI:10.1177/1073858420939033
PMID:32659199
Abstract

COVID-19 is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world. SARS-CoV-2 is the virus causing COVID-19. Acute respiratory distress syndrome (ARDS) is definitely one of the main clinically relevant consequences in patients with COVID-19. Starting from the earliest reports of the COVID-19 pandemic, two peculiar neurological manifestations (namely, hyposmia/anosmia and dysgeusia) were reported in a relevant proportion of patients infected by SARS-CoV-2. At present, the physiopathologic mechanisms accounting for the onset of these symptoms are not yet clarified. CXCL10 is a pro-inflammatory chemokine with a well-established role in the COVID-19-related cytokine storm and in subsequent development of ARDS. CXCL10 is also known to be involved in coronavirus-induced demyelination. On these bases, a role for CXCL10 as the common denominator between pulmonary and olfactory dysfunctions could be envisaged. The aim of the present report will be to hypothesize a role for CXCL10 in COVID-19 olfactory dysfunctions. Previous evidences supporting our hypothesis, with special emphasis to the role of CXCL10 in coronavirus-induced demyelination, the anatomical and physiological peculiarity of the olfactory system, and the available data supporting their link during COVID-19 infections, will be overviewed.

摘要

新型冠状病毒肺炎(COVID-19)是一种正在流行的病毒性疾病,起源于东亚,并迅速传播到世界其他地区。引发 COVID-19 的病原体是严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。急性呼吸窘迫综合征(ARDS)是 COVID-19 患者的主要临床相关后果之一。从 COVID-19 大流行的最早报告开始,就有相当比例的 SARS-CoV-2 感染者报告了两种特殊的神经表现(即嗅觉减退或丧失和味觉障碍)。目前,这些症状发生的病理生理机制尚不清楚。趋化因子(C-X-C 基元)配体 10(CXCL10)是一种促炎趋化因子,在 COVID-19 相关细胞因子风暴和随后的 ARDS 发展中具有明确的作用。CXCL10 也已知与冠状病毒诱导的脱髓鞘有关。基于这些发现,我们可以推测 CXCL10 在 COVID-19 嗅觉功能障碍中起着共同作用。本报告的目的将假设 CXCL10 在 COVID-19 嗅觉功能障碍中的作用。将综述支持我们假设的先前证据,特别强调 CXCL10 在冠状病毒诱导的脱髓鞘、嗅觉系统的解剖和生理学特征以及支持 COVID-19 感染期间它们之间联系的现有数据中的作用。

相似文献

1
COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?COVID-19 肺部和嗅觉功能障碍:趋化因子 CXCL10 是否为共同决定因素?
Neuroscientist. 2021 Jun;27(3):214-221. doi: 10.1177/1073858420939033. Epub 2020 Jul 13.
2
Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!白细胞介素-6、CXCL10 和浸润巨噬细胞在 COVID-19 相关细胞因子风暴中的作用:不是一荣俱荣,而是众志成城!
Front Immunol. 2021 Apr 26;12:668507. doi: 10.3389/fimmu.2021.668507. eCollection 2021.
3
The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner.促炎趋化因子 CXCL9、CXCL10 和 CXCL11 在 SARS-CoV-2 感染后呈 AKT 依赖性上调。
Viruses. 2021 Jun 3;13(6):1062. doi: 10.3390/v13061062.
4
Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19).嗅觉丧失:2019 年冠状病毒病(COVID-19)神经免疫中的缺失环节。
Rev Neurosci. 2020 Oct 25;31(7):691-701. doi: 10.1515/revneuro-2020-0039.
5
[Loss of smell, a preliminary indicator of COVID-19].[嗅觉丧失,新冠病毒病的一个初步指标]
Rev Med Inst Mex Seguro Soc. 2021 Feb 2;59(1):4-6. doi: 10.24875/RMIMSS.M21000046.
6
Does COVID-19 cause permanent damage to olfactory and gustatory function?新冠病毒会对嗅觉和味觉功能造成永久性损害吗?
Med Hypotheses. 2020 Oct;143:110086. doi: 10.1016/j.mehy.2020.110086. Epub 2020 Jul 9.
7
Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19.口干、味觉和嗅觉障碍在 COVID-19 患者中的表现。
Am J Otolaryngol. 2020 Nov-Dec;41(6):102721. doi: 10.1016/j.amjoto.2020.102721. Epub 2020 Sep 10.
8
The Importance of Considering Olfactory Dysfunction During the COVID-19 Pandemic and in Clinical Practice.重视 COVID-19 大流行期间及临床实践中的嗅觉功能障碍
J Allergy Clin Immunol Pract. 2021 Jan;9(1):7-12. doi: 10.1016/j.jaip.2020.10.036. Epub 2020 Oct 28.
9
Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection.SARS-CoV-2 感染患者嗅觉和味觉功能障碍的危险因素。
Neuroepidemiology. 2021;55(2):154-161. doi: 10.1159/000514888. Epub 2021 Apr 1.
10
Olfactory and rhinological evaluations in SARS-CoV-2 patients complaining of olfactory loss.SARS-CoV-2 患者嗅觉丧失时的嗅觉和鼻科学评估。
Rhinology. 2020 Aug 1;58(4):400-401. doi: 10.4193/Rhin20.136.

引用本文的文献

1
A20 as a Potential Therapeutic Target for COVID-19.A20作为新冠病毒病的潜在治疗靶点
Immun Inflamm Dis. 2025 Jan;13(1):e70127. doi: 10.1002/iid3.70127.
2
In-silico discovery of common molecular signatures for which SARS-CoV-2 infections and lung diseases stimulate each other, and drug repurposing.计算机模拟发现 SARS-CoV-2 感染和肺部疾病相互刺激的共同分子特征,并进行药物再利用。
PLoS One. 2024 Jul 18;19(7):e0304425. doi: 10.1371/journal.pone.0304425. eCollection 2024.
3
Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect?
棕榈酰乙醇胺和木犀草素用于感染后嗅觉障碍:其效果在临床上有多大意义?
ORL J Otorhinolaryngol Relat Spec. 2024;86(3-4):118-123. doi: 10.1159/000539651. Epub 2024 Jun 11.
4
BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.BPR3P0128 是一种非核苷类 RNA 依赖性 RNA 聚合酶抑制剂,能够抑制 SARS-CoV-2 关切变异株,并与瑞德西韦联合具有协同抗病毒活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0095623. doi: 10.1128/aac.00956-23. Epub 2024 Mar 6.
5
Microglial Inflammatory Responses to SARS-CoV-2 Infection: A Comprehensive Review.《对 SARS-CoV-2 感染的小胶质细胞炎症反应:全面综述》。
Cell Mol Neurobiol. 2023 Dec 15;44(1):2. doi: 10.1007/s10571-023-01444-3.
6
Featured immune characteristics of COVID-19 and systemic lupus erythematosus revealed by multidimensional integrated analyses.多维综合分析揭示的COVID-19和系统性红斑狼疮的特征性免疫特性
Inflamm Res. 2023 Sep;72(9):1877-1894. doi: 10.1007/s00011-023-01791-3. Epub 2023 Sep 19.
7
The Association between Dysnatraemia during Hospitalisation and Post-COVID-19 Mental Fatigue.住院期间低钠血症与新冠后精神疲劳之间的关联
J Clin Med. 2023 May 26;12(11):3702. doi: 10.3390/jcm12113702.
8
Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study.重症 COVID-19 后持续存在的耗竭性 T 细胞免疫:一项前瞻性观察研究的 6 个月评估
J Clin Med. 2023 May 18;12(10):3539. doi: 10.3390/jcm12103539.
9
Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio.暴露于不同四氢大麻酚(THC)与大麻二酚(CBD)比例的大麻烟雾中的小鼠肺部的差异炎症特征。
Arch Toxicol. 2023 Jul;97(7):1963-1978. doi: 10.1007/s00204-023-03514-3. Epub 2023 May 14.
10
A comprehensive analysis of gene expression profiling data in COVID-19 patients for discovery of specific and differential blood biomarker signatures.对 COVID-19 患者的基因表达谱数据进行全面分析,以发现特异性和差异性的血液生物标志物特征。
Sci Rep. 2023 Apr 5;13(1):5599. doi: 10.1038/s41598-023-32268-2.